In a pronouncement with implications for companies such as AstraZeneca PLC and Novavax, Inc., the Drugs Controller General of India (DCGI), V G Somani, has said the country’s regulatory body does not plan to permit emergency use authorizations (EUAs) for COVID-19 vaccines before the completion of clinical trials.
His comment at a virtual edition of the Annual BioPharma and Healthcare Summit of the USAIC (USA-India Chamber of Commerce)...







